Vladimír Maisnar

4.3k total citations
80 papers, 467 citations indexed

About

Vladimír Maisnar is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Vladimír Maisnar has authored 80 papers receiving a total of 467 indexed citations (citations by other indexed papers that have themselves been cited), including 66 papers in Hematology, 51 papers in Molecular Biology and 41 papers in Oncology. Recurrent topics in Vladimír Maisnar's work include Multiple Myeloma Research and Treatments (62 papers), Protein Degradation and Inhibitors (30 papers) and Peptidase Inhibition and Analysis (21 papers). Vladimír Maisnar is often cited by papers focused on Multiple Myeloma Research and Treatments (62 papers), Protein Degradation and Inhibitors (30 papers) and Peptidase Inhibition and Analysis (21 papers). Vladimír Maisnar collaborates with scholars based in Czechia, United States and Spain. Vladimír Maisnar's co-authors include Roman Hájek, Jiří Minařík, Luděk Pour, Ivan Špıčka, Jakub Radocha, J Malý, Evžen Gregora, Paul G. Richardson, Vlastimil Ščudla and María‐Victoria Mateos and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Annals of Oncology.

In The Last Decade

Vladimír Maisnar

65 papers receiving 450 citations

Peers

Countries citing papers authored by Vladimír Maisnar

Since Specialization

Citations

This map shows the geographic impact of Vladimír Maisnar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Vladimír Maisnar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Vladimír Maisnar more than expected).

Fields of papers citing papers by Vladimír Maisnar

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Vladimír Maisnar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Vladimír Maisnar. The network helps show where Vladimír Maisnar may publish in the future.

Co-authorship network of co-authors of Vladimír Maisnar

This figure shows the co-authorship network connecting the top 25 collaborators of Vladimír Maisnar. A scholar is included among the top collaborators of Vladimír Maisnar based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Vladimír Maisnar. Vladimír Maisnar is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Lenalidomide based triplets in relapsed/refractory multiple myeloma: analysis of the Czech Myeloma Group 2025 ·BMC Cancer ·Jiří Minařík, Luděk Pour, (unknown), Tomáš Jelı́nek, Jan Štraub, Alexandra Jungová, Jakub Radocha, (unknown), (unknown), Tomáš Pika, (unknown), (unknown), František Sedlák, (unknown), Pavel Jindra, (unknown), Vladimír Maisnar, Roman Hájek	0
2	Evolution of Treatment Patterns and Survival Outcomes in European Patients with Multiple Myeloma from 2012-2023 through the Honeur Federated Data Network 2024 ·Blood ·Michael Rückert, (unknown), Mamta Garg, Ceri Bygrave, (unknown), (unknown), Kristina Bardenheuer, (unknown), Morten Salomo, (unknown), (unknown), (unknown), Joris Diels, Vladimír Maisnar, Ivan Špıčka, Roman Hájek	0
3	A Multicenter Phase 2 Study Evaluating the Optimized Schedule of Belantamab Mafodotin 1.9 Mg/Kg Q8W Plus Bortezomib and Dexamethasone in Relapsed Refractory Multiple Myeloma 2024 ·Blood ·(unknown), Jakub Radocha, (unknown), Jiří Minařík, Jan Štraub, Alexandra Jungová, (unknown), Tomáš Jelı́nek, Vladimír Maisnar, Luděk Pour, Tomáš Pika, František Sedlák, J. Soukup, (unknown), (unknown), Viera Sandecká, (unknown), David Žihala, Roman Hájek	0
4	Daratumumab with lenalidomide and dexamethasone in relapsed or refractory multiple myeloma patients – real world evidence analysis 2023 ·Annals of Hematology ·Martin Štork, Ivan Špıčka, Jakub Radocha, Jiří Minařík, Tomáš Jelı́nek, Alexandra Jungová, (unknown), Lenka Pospíšilová, František Sedlák, Jan Štraub, Tomáš Pika, (unknown), (unknown), (unknown), Sabina Ševčı́ková, Vladimír Maisnar, Roman Hájek, Luděk Pour	6
5	P1294: REAL-WORLD OUTCOMES OF 2149 NEWLY DIAGNOSED TRANSPLANT-ELIGIBLE MULTIPLE MYELOMA PATIENTS 2023 ·HemaSphere ·(unknown), Luděk Pour, Ivan Špıčka, Jakub Radocha, Alexandra Jungová, Jiří Minařík, (unknown), Tomáš Jelı́nek, Marta Krejčí, Jan Štraub, Vladimír Maisnar, (unknown), Tomáš Pika, J. Soukup, Lenka Pospíšilová, Roman Hájek	1
6	P34 LIGHTHOUSE (OP-108): MELFLUFEN PLUS DARATUMUMAB (DARA) AND DEXAMETHASONE (DEX) VERSUS DARA IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) REFRACTORY TO AN IMMUNOMODULATORY DRUG (IMID) AND A PROTEASOME INHIBITOR (PI) OR HAD RECEIVED ≥3 PRIOR LINES OF THERAPY INCLUDING AN IMID AND A PI 2023 ·HemaSphere ·María‐Victoria Mateos, (unknown), Jelena Bila, Fredrik Schjesvold, (unknown), Vladimír Maisnar, Artur Jurczyszyn, (unknown), Roman Hájek, Ganna Usenko, Marcus Thuresson, Stefan Norin, (unknown), PG Richardson, Luděk Pour	1
7	Unexpected Heterogeneity of Newly Diagnosed Multiple Myeloma Patients with Plasmacytomas 2022 ·Biomedicines ·Martin Štork, Sabina Ševčı́ková, Tomáš Jelı́nek, Jiří Minařík, Jakub Radocha, Tomáš Pika, Lenka Pospíšilová, Ivan Špıčka, Jan Štraub, (unknown), Alexandra Jungová, (unknown), Viera Sandecká, Vladimír Maisnar, Roman Hájek, Luděk Pour	2
8	Patient Characteristics, Treatment Patterns, and Outcomes in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma Patients, a Retrospective Observational Study Using Czech Registry Data 2022 ·Clinical Lymphoma Myeloma & Leukemia ·Vladimír Maisnar, Luděk Pour, Ivan Špıčka, Tomáš Jelı́nek, Jiří Minařík, Alexandra Jungová, Martin Štork, Jan Štraub, Jakub Radocha, Tomáš Pika, Lenka Pospíšilová, Sandhya Nair, (unknown), Roman Hájek	4
9	Ixazomib, Lenalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma in Routine Clinical Practice: Extended Follow-Up Analysis and the Results of Subsequent Therapy 2022 ·Cancers ·Jiří Minařík, Jakub Radocha, Alexandra Jungová, Jan Štraub, Tomáš Jelı́nek, Tomáš Pika, Luděk Pour, (unknown), (unknown), Lenka Pospíšilová, (unknown), (unknown), Pavel Jindra, Ivan Špıčka, (unknown), Martin Štork, Jaroslav Bačovský, Vladimír Maisnar, Roman Hájek	5
10	Real-world evidence of efficacy and safety of pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients: Czech registry data 2022 ·Neoplasma ·Viera Sandecká, Luděk Pour, Ivan Špıčka, Jiří Minařík, Jakub Radocha, Tomáš Jelı́nek, (unknown), Alexandra Jungová, (unknown), (unknown), (unknown), Jan Štraub, Tomáš Pika, (unknown), (unknown), Vladimír Maisnar, Roman Hájek	2
11	Methodology and results of real-world cost-effectiveness of carfilzomib in combination with lenalidomide and dexamethasone in relapsed multiple myeloma using registry data 2019 ·The European Journal of Health Economics ·(unknown), Ion Agirrezabal, Roman Hájek, Jiří Minařík, Luděk Pour, (unknown), Sebastian Gonzalez‐McQuire, (unknown), Vladimír Maisnar	5
12	Lenalidomide and dexamethasone in treatment of patients with relapsed and refractory multiple myeloma – analysis of data from the Czech Myeloma Group Registry of Monoclonal Gammopathies 2019 ·Neoplasma ·Vladimír Maisnar, (unknown), (unknown), Luděk Pour, Jiří Minařík, (unknown), Jakub Radocha, Evžen Gregora, (unknown), Tomáš Jelı́nek, Alexandra Jungová, Eva Králíková, (unknown), Roman Hájek	5
13	Diagnostika a léčba Waldenströmovy makroglobulinemie 2014 ·Zdeněk Adam, Roman Hájek, Marta Krejčí, Vladimír Maisnar, Lucie Říhová, Sabina Ševčı́ková, David Belada, (unknown), Marek Trněný	0
14	Complex karyotype and translocation t(4;14) define patients with high-risk newly diagnosed multiple myeloma: results of CMG2002 trial 2011 ·Leukemia & lymphoma ·Pavel Němec, Zuzana Zemanová, Petr Kuglík, K Michalová, (unknown), (unknown), Alexandra Oltová, (unknown), (unknown), (unknown), Marie Jarošová, (unknown), (unknown), Ivan Špıčka, Evžen Gregora, Zdeněk Adam, Vlastimil Ščudla, Vladimír Maisnar, (unknown), Roman Hájek, (unknown)	34
15	Diagnosis and surgical therapy of plasma cell neoplasia of the spine 2009 ·Neoplasma ·(unknown), Vladimír Maisnar, (unknown), (unknown), Pavel Ryška, (unknown), (unknown)	4
16	Monoklonálne gamapatie nejasného významu. 2008 ·Klinicka onkologie ·Viera Sandecká, Vladimír Maisnar, Luděk Pour, (unknown), Roman Hájek	0
17	[Monoclonal gammopathies of undetermined significance]. 2008 ·PubMed ·(unknown), Vladimír Maisnar, Luděk Pour, Jakub Radocha, Roman Hájek	1
18	Pozdní diagnostika páteřního postižení u myelomu 2006 ·Neurologie pro praxi ·(unknown), Vladimír Maisnar, (unknown), (unknown), Pavel Ryška, (unknown), (unknown), (unknown), (unknown), (unknown)	0
19	Evaluation of the Czech External Quality Assessment System of monoclonal immunoglobulin in the period of 1996-2005 2006 ·(unknown), (unknown), Ctirad Andrýs, Vladimír Maisnar, J Vávrová, (unknown), (unknown), Roman Hájek, Vladimír Palička	1
20	Long-Term Results in Hairy Cell Leukemia Treated with 2-Chlorodeoxyadenosine 1997 ·Acta Medica (Hradec Kralove Czech Republic) ·L Chrobák, Павел Зак, (unknown), Lenka Plíšková, (unknown), Vladimír Maisnar, Petr Ďulíček, (unknown)	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact